Giancarlo Comi.

Adverse-event analysis was based on the %age of patients who discontinued the study and the %age of patients who discontinued the study owing to adverse events. Statistical Analysis We estimated that a sample of 1000 patients would provide 90 percent power to detect a significant switch in the annualized relapse price, assuming an expected annualized relapse price of 0.65 among untreated individuals, a 25 percent or greater decrease in the annualized relapse rate with laquinimod in comparison with placebo, and a 20 percent price of withdrawal from the analysis over an interval of two years.The curved lines indicate the hypothetical prevalence of the potential confounder in the CABG group. For instance, if an unmeasured risk aspect was present in 10 percent of the sufferers in the CABG group and in 20 percent, 35 percent, or 50 percent of the sufferers in the PCI group, then the hazard ratio that would be necessary for an unmeasured confounder to account for the observed reduced risk with CABG would be 4.25, 2.09, and 1.65, respectively. Likewise, if an unmeasured risk factor was within 20 percent of the individuals in the CABG group and in 30 percent, 45 percent, or 60 percent of the individuals in the PCI group, then your hazard ratio that might be required for an unmeasured risk aspect to account for the observed improved risk with PCI would be 5.82, 2.22, and 1.70, respectively.